Member Info for rob229

in the first sentence.

Yes, nice to see a rise today. This board remains very quiet. Approx. three months ago, you and I exchanged greetings regarding this good. The fundamentals still seem favorable. The quietness of the board means to me that the company is yet to be discovered. I sense that you subscribe to the proverb "Good things come to he who waits." Rob

The news item of mid-December, as to the hiring of the new vice president, seems to have been favorably received by the market. Her c.v., setting forth apparently successful associations with both Oracle and Adobe, looks impressive to me. I remain a patient watcher. Perhaps you too.

I am the shareholder who posted a message here on 01 Aug. 2017, shortly after the name change. I sense something auspicious at ALB. Consequently, I should think there would be some communicators on this board. Perhaps someone will say hello and will share some thoughts. I am lonely! Good luck to all.

Hello Mr Costello, I thank you for mentioning GDV. I seem to remember looking at GDV when it was still known as Epistem. (I have been in TEK for several months, and it has been my inclination to hold for the long term because I like the idea that TEK has stakes in various promising technologies. I feel as though only a few successes are needed in order for the TEK share to be propelled.) Meanwhile, I wonder if you would take a few minutes to set forth your view as to the viability of GDV (versus OraSure). I was reading that the Hep C test offered by GDV has a capacity to operate without a considerable capital-equipment outlay by a clinic. (Apparently, OraSure testing requires a considerable capital outlay.) Anyway, I am wondering whether the non-need for a considerable capital investment by a clinic that offers its patients the genedrive test is one of the main reasons that you sense that, in due course, GDV will thrive? The share structure at GDV looks quite good. In other words, it is nice to see that institutions are apparently very keen on the story. I thank you for sharing your thoughts when you have a moment. Kind regards, rob229

I may be less witty than Costello, but I am here too. I feel as though the TEK share has just not been on investors' radar screen. As most AIM investors know, promising fundamentals are routinely overlooked. A catalyst is needed. Perhaps the recent news is a sufficient catalyst. Perhaps the news caused someone to include the TEK share in a column somewhere. I wish good luck to all. Rob

I am surprised that no one has posted here yet. To me, Albert Technologies seems like a winner. I admit to being old-fashioned. I still sign documents with a fountain pen, and I do not plan to switch to a ballpoint pen. I may not understand exactly what Albert Technologies does, yet I know that I like both (a) the sector and (b) the shareholder structure. Because I have a strong, intuitive sense that the management is conscientious and talented, I intend to be patient.

You and I think alike. I feel as though we both believe in this company. Seeing that the market is, for the present, not in accord is dispiriting. I would like to see some share purchases by those who have reportable interests. Rob

I just want to say that, in my experience, a turnaround here is going to be a slow process. I decided just now to take my loss and take a punt on Seeing Machine (AIM: SEE). The news and the chatter feel very promising there. I am far from England, so my access to information may be less satisfactory than the access of others here. I know that I prefer to hitch my wagon to a company that is not stumbling. I concede that it hurts to have taken the loss in Quantum. Had I made the switch on 3 October, I could have bought many more SEE shares. I used to know a very smart solicitor (now retired) who would -- at a time like this -- have said, "Yes, but that was then; and now is now." I'm just trying to respond to changing conditions. I welcome the comments of others. If you are going to disparage me, I hope you will be gentle about the disparagement. Good luck to all.

Thank you for writing, Mr gg_man, When I encounter a communicator such as you, who writes well and is trying to be helpful, I sometimes have the judgment to ask what other companies the communicator may be following. I see that, a couple of months ago, you were interested in DUKE. I spent some time looking at the company. Maybe it is under-followed and very attractively valued in the 40p range. Very respectfully, I ask whether you continue to follow DUKE. Thank you much. Rob

Hello to Mr gg_man, I am very far from London, and I will not be able to attend the 7th April presentation. I suppose that several will summarize here Cathal's presentation. I hope you will be among those who will share impressions. Do we know the timetable for the FAST share to be traded again? I like the story very much, but being locked in is (IMO) no fun. Thank you most kindly for considering this post. Regards, Rob

Good morning on 26.10.2015, I found my way to this share within the past few days. I can see that you are a highly numerate individual and that you have studied the company intensively. For the reason that the mining sector has been out of favor for a long time, I am generally cautious about mining shares, but I strongly sense value here. I will watch carefully the early trading today. Maybe it is unwise to attach significance to the fact that the list of 3+ per cent shareholders includes (a) Goldman Sachs and (b) Fidelity and (c) Sprott, but three such reputable shareholders are, to my way of thinking, noteworthy. I realize everyone makes mistakes sometimes, but still I have confidence in this triumvirate. I was noticing your 18.09.2015 post in which you comment on the value of OMI assets in relation to the capitalization. I am just wondering whether the ~ 16.5 mil. USD current valuation for the long-term asset described as "exploration and evaluation _____" is, in your opinion, correct in light of the long-term weakness in the price of gold. I am not claiming to know the answer, I am just asking the question. Thank you for your consideration of this message. Rob

Hello to Mr Yellow Snow, I appreciate your having posted on 08 October the link to GOS systems. Just this morning,I noticed your message when I was trying to bring myself current with regard to some companies. I will study the gold share that you mentioned just a bit before your 08 October post on the TGL board in which you set forth the link to GOS. I can tell that you are a knowledgeable person, and I can benefit these days from the competent assistance of others. Rob

I too wish I could add to my position in TGL. I write from some distance (US), and I have no crystal ball. To my mind, TGL would not have been inclined to schedule the 09/09/2015 conference call unless prospects are good. Methinks TGL would just issue a news release if the discussion were likely to be received poorly. To my knowledge, there is no obligation to have a conference call. I wish TGL holders the best. Rob

of all. Will wait patiently for the reopening of trading in the shares of TGL. I do not know whether a suggestion of Opsens, Inc., a share quoted only in Canada, is a reasonable way to return the kindness of those who responded. I see some potential in Opsens, Inc., which have received approval both by FDA (the US drugs-approving agency) and the European Medicines Agency of a type of medical equipment that may be beneficial in the realm of cardiology care. The market cap of Opsens, Inc. is ca. 55 million Canadian dollars. No significant revenues from this line of business yet, and I realize that either (a) time and money or (b) an agreement with a larger entity that can help grow revenues may be needed. Still, 55 million Canadian dollars seems inexpensive for a company with an approved type of medical equipment. Just my opinion, but I am impressed. Hopefully you can see that i am not a ramper. Good luck to all. Rob

Hello sir, thank you for writing. I confess that i have not paid adequate attention. I just liked the story and the idea that it is (in spite of the name) not presently a mining company. This fact strongly suggested to me undervaluation. I infer from your message and from the general quiet on this board that shareholders are not upset about the suspension; so I will not allow myself to be upset. I can see that, during the weekend, I have some reading to catch up on. By the way, I write from the US, so keeping track of my London shares is a little extra work. Are you happy to be involved with TGL? Thank you again for the update. Kind regards, Rob

as to when a lifting of the temporary suspension is likely? Thank you. Rob

Good day sir, I imagine that you have no need for me to say, with regard to the company about which you have kindly written at length, that you have done your homework. I know one thing for sure: not infrequently, successful share investing requires patience. I have encountered more than one investor who has said (as you suggest) that the gains often arrive more that 1-2 years after becoming interested. Some of my own experience has been like that. More than once, I sold shares at a small loss after becoming impatient with the prospects; then I checked back a year later and realized that taking the small loss was not the answer. I see that the stock exchange in Sydney is closed on 08 June 2015 for the Queen's Birthday. You know, I journeyed some years ago to your adopted country of New Zealand, and I was impressed (just as I knew that I would be). But the word "kauri," which I have just now learned is an important tree, was not discovered by me during my visit. Thank you again for sharing your knowledge. I hope you will write again. Regards, rob229

Hello on Saturday to Mr Kauri, I write both because (a) the 05 June 2015 news of the acquisition of the Spanish company by AGY impresses me in light of the small size of AGY and because (b) I am struck by the optimism that you express in connection with Immuron. Those $10-$20 price objectives of yours for Immuron suggest great confidence in that which Immuron is doing. When last evening I visited the Immuron website, I was struck that IMC is not just developing the antidote for NASH but also that IMC does already have a commercialized product, "Travelan," which has been approved for sale in some markets. This product might, in the minds of some, be a candidate for snickering; but for anyone who has had the misfortune of sustaining gastrointestinal illness while present in tropical climates, there is nothing funny about such illness. I cannot recall at the moment whether the link that you attached did separately mention the commercialized product, namely Travelan. In any event, I am impressed that this small company has so much going for it: Travelan and two drugs in Phase II trials. I am wondering whether your professional calling may have equipped you to understand why IMC is, in your judgment, such a promising company. Maybe you are a medical researcher. I infer that you are, along with most of the posters here, residing in England. In any event, I would imagine that you are not residing in Victoria, Australia. I concede that it is not any of my business, but maybe you would consider telling me the reason or reasons that have given you confidence in the NASH antidote which IMC is developing. Thank you very much. Kind regards, rob229

Hello Mr Kauri, Thank you for attaching the report re IMC trading in Sydney. I write from the US. I have encountered pharma companies in Australia in the past, and they are in earnest, like people everywhere else. Maybe IMC has potential. I will give it a look today. By way of exchanging suggestions, I am interested in a Canadian pharma named Tribute Pharmaceuticals. The symbol is TRX, quoted in Toronto on the Venture board (where the less well-established companies trade). I urge caution, but they seem to be moving in a good direction. Your own independent research is certainly essential before making any commitment. I mention the company because I like to do my part. Regards (and GLTA), Rob229